



Revolutionizing Temperature-Controlled Medication Storage with Patented Space-Grade Technology

The only temperature insulating case with space grade technology. Patented and Validated.



Disclaimer

This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any security and may not be relied upon in connection with the purchase or sale of any security issued by the Company. Any such offer would only be made by means of definitive investment documents, the terms of which would govern in all respects.

You should not rely on the Presentation as the basis upon which to make any investment decision. This material does not purport to be all-inclusive or to contain all the information that a prospective investor may desire to consider in determining whether to make an investment. It is your obligation to conduct your own due diligence in making an investment decision. This material is provided for informational purposes only. To the extent that you rely on the Presentation in connection with any investment decision, you do so at your own risk. No person has been authorized to make any statement concerning the investment and any such statement, if made, may not be relied upon by you. Only those particular representations and warranties which may be made by the Company or its Officers in definitive investment documents, if and when they are executed, and subject to such limitations and restrictions as may be specified in such documents, may be relied upon and have any legal effect. Certain provisions of the investment documents are summarized in this Presentation, but you should not assume that the summaries are complete. Such summaries are qualified in their entirety by reference to the texts of the original documents.

The Presentation is not intended to provide, and should not be relied upon for, tax, legal, accounting or investment advice. You should consult your own attorneys, business advisers and tax advisers as to the investment and as to the tax, legal, accounting, business and other related matters. Any statements of federal tax consequences contained in the Presentation were not intended to be used and cannot be used to avoid penalties under the Internal Revenue Code or to promote, market or recommend to another party any tax related matters addressed herein. An investment in the Company involves risk of loss of all or part of your investment. Investors should have the financial ability and willingness to accept the risks associated with such investment.

Any projections or other estimates in this Presentation, including estimates of returns or performance, are forward-looking statements and are based upon certain assumptions. Other events, which were not taken into account, may occur and may significantly affect the outcome. Any assumptions should not be construed to be indicative of the actual events that will occur. Actual events are difficult to predict and may depend upon factors that are beyond the control of the Company or its Officers or Directors, and, accordingly, actual results will differ, and may differ significantly, from those presented. Certain information contained in the Presentation includes calculations or figures that have been prepared internally and have not been audited or verified by a third party. Use of different methods for preparing, calculating or presenting information may lead to different results, and such differences may be material.

Except where otherwise indicated, the information contained in the Presentation has been compiled as of May 2025 and none of the Company or its Officers or Directors has any obligation to update the Presentation. Under no circumstances should delivery of the Presentation create any implication that there have been no changes in the information contained in the Presentation since the date set forth above.

Investment Highlights



- **Untapped Market Potential:**
Over 160 million patients use temperature sensitive medications every day globally; \$30BN total addressable market (TAM).
- **Proprietary, Patented Technology:**
4 products in market. 8 patents globally. Space grade technology that keeps medication at optimal temperatures. First protective storage solution that is compact, hassle-free and user friendly, charging free, works 24/7/365 for years, no maintenance required. Over 120,000 units sold to date, high customer satisfaction rate with 30% repeat buys.
- **Global Distribution Capabilities:**
Manufactured and assembled in the USA with current production capacity of 1M units/year (~US\$70 million in sales)
- **Strong Validation & Market Adoption:**
Distribution with large pharmacy, government and retail networks including: *Humana, Maccabi, CVS, Walmart, Walgreens, Amazon, McKesson, Target, US Department of Veteran Affairs.*
- **Aggressive Growth Strategy with Robust Pipeline:**
Pivoting from B2C online model to B2B/Payor model. Future distribution partnerships, expanding product portfolio to include SAAS model, entering new market verticals, brick and mortar pharmacy networks and partnerships with Payors and HMOs
- **Strong Recurring Revenue Profile:**
US\$2.2 Million in 2024, projected rev +US\$15M in 2026 and targeting cash flow positive.

Transforming Medication Safety at Scale



Our Vision
"Make every injectable device connected and temperature-protected."

Market Opportunity

160M+

Patients worldwide at risk from medication temperature exposure.

Total Addressable Market

Diabetes, Allergy, Biologics

Competitive Moat

- ★ **First-Mover Advantage**
Only comprehensive connected solution.
- ★ **Proven ROI Model**
Validated cost savings for payors.
- ★ **Strong IP Portfolio**
Global patents covering thermal + smart tech.
- ★ **Diverse Product Suite**
Serving pens, vials, and auto-injectors.

2026 Objectives

- ✓ **\$15M+ Revenue Target**
Driven by institutional B2B contracts.
- ✓ **Reimbursement Secured**
Establishing recurring revenue streams.
- ✓ **Global Footprint**
Active distribution in 10+ key markets.
- ✓ **Path to Profitability**
Scale manufacturing & optimize margins.

Single Product to Comprehensive Platform

Product Portfolio Expansion



VIVI Cap

The core original product providing validated temperature protection for insulin pens without electricity or batteries.

- ✓ 24/7 Temperature shield
- ✓ Maintenance free
- ✓ Fit & forget design



New

VIVI Cap Smart

Next-generation connected device integrated with a mobile app and subscription model for enhanced patient monitoring.

- ✓ Real-time temp monitoring
- ✓ App connectivity
- ✓ Subscription revenue



New

VIVI Med

Expanded protective solution designed for vials, biologics, GLP-1 therapies, and temperature-sensitive test strips.

- ✓ Fits standard vials
- ✓ Covers GLP-1 / Biologics
- ✓ Protects test strips



VIVI Epi

Relaunched marketing initiative for epinephrine auto-injector protection, addressing critical allergy markets.

- ✓ EpiPen compatible
- ✓ Critical heat protection
- ✓ Life-saving reliability




Opportunities to expand into different categories: multi product VIVI Box (end 2026), blood transfer, military and ambulance applications

Proven Market Penetration

VA | U.S. Department
of Veterans Affairs

MCKESSON

Maccabi
Healthcare Services

 Yale University
School of Medicine

Walgreens

 **CVS** pharmacy®

 **cigna**
healthcare™

Optum Store

 AmerisourceBergen®

 **HENRY SCHEIN**®

MEDLINE

 **Humana**

Morris & Dickson

 **Premier**
HEALTHCARE SERVICES

 **CardinalHealth**

 **TARGET**

amazon


 **shopify**

Walmart 

Simply **Medical**

Proprietary Technology Platform

Combining features used in Spacecraft, Avionics and Medical Cryotherapy



Creating hassle-free, lightweight and easy to carry products that maintain proper temperature of injectable medications for years, without any maintenance or requiring external energy source.

Recurring Revenue, Introducing SAAS Model

Over 120,000 units sold, customers repeat buys, high satisfaction rate



Institutional B2B Strategy

Channels: Payor, Pharmacy, Provider



1. Payor/HMO Engagement

Reimbursement & Coverage

ROI Validated

Leveraging Partnerships

- ✓ Launch ROI-driven pilot programs with validated model
- ✓ Secure formal reimbursement pathways
- ✓ Utilize real-world evidence from Maccabi case studies



2. Pharmacy Distribution

Retail & Dispensing

Global Scale

Existing: Israel, Benelux, Turkey

- ✓ Expand existing footprint (2,500+ outlets in Israel)
- ✓ Pursue major U.S. pharmacy chains (e.g., Walgreens)
- ✓ In-pharmacy merchandising & staff education



3. Provider Outreach

Clinical Advocacy

Prescription Drive

Key Opinion Leaders

- ✓ Target endocrinologists & diabetes educators
- ✓ Disseminate clinical evidence & stability data
- ✓ Implement prescription recommendation programs



4. Pharma Partnerships

Force Multiplier



Co-Marketing

Joint campaigns with insulin/GLP-1 manufacturers to enhance medication safety.



Bundled Offerings


Packaging VIVI products with medication prescriptions for total solution value.



Institutional adoption drives volume and recurring revenue.

Execution Roadmap

Key 2026 Milestones & Initiatives



Quarterly milestones ensuring accountability and momentum throughout 2026.

ROI Reimbursement Model

Validation and positive feedback from leading 3rd party Validation Institute in the United States

- ✓ ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility
- ✓ Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment
- ✓ Supports TempraMed's planned payor pilot programs aimed at confirming savings and securing reimbursement coverage
- ✓ Establishes a scalable, reimbursement-driven growth pathway with significant upside potential for investors



Experienced Management Team



ILAN COHEN
Executive Chairman

Serial entrepreneur and Former Director of the Israeli Prime Minister's office.



RON NAGAR
Founder & CEO

Medical device serial entrepreneur and inventor. Co-Founder InsuLine Medical and Glucon.



GABI KABAZO
CFO

20+ years of experience in accounting, finance and IT operations in complex corporate settings.



DANIEL SALOMON
General Manager, America

Ex Teva Executive, 17 years at Teva. Served as Head of Sales and Marketing for Teva USA institutional business unit.



PROF. ANDREAS PFÜTZNER, M.D.
Medical Director

Managing Director and Founder of PFÜTZNER Science & Health Institute GmbH, Germany.



DR. TAMIR GEDO
Chairman, Advisory Board

+25 years as a marketing and business strategy expert serving in academic, government, and industry functions



JULIA BECKER
VP, Capital Markets

15 years experience in capital markets, investor relations, and business development specializing in building strategic relationships.

Board / Advisors



SUSAN ALPERT, MD, PhD
Chief Regulatory Advisor

Former Director of Device Evaluation at the FDA, Senior VP Global Regulatory.



JULIA BECKER
Board of Directors

15 years experience in capital markets, investor relations, and business development.



NANCY GOERTZEN
Board of Directors

Experienced corporate director and has over 30 years' experience in capital markets across multiple industry sectors.



JOHN SINCLAIR
Board of Directors

Senior business strategist and advisor, a CPA and CA with over 40 years of global experience.



BRIAN HOPKINS, JD
IP Counsel

US IP attorney with over 25 years of experience in intellectual property.



PROF. WILLIAM V. TAMBORLANE
Scientific & Medical Advisor

Honored Professor and Chief of Pediatric Endocrinology at Yale School of Medicine.



DR. DIANA ISAACS
Medical Advisor

Endocrine Clinical Pharmacist. 2020 ADCES Diabetes Care & Education Specialist of the Year.



Lutz Heinemann, PhD.
Scientific Advisory Board

A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability .

Capital Structure

Public in October 2025

CSE: "VIVI"

RTO Financing: C\$7.4M

*Subsequent Financing: C\$2.5M
(Complete Jan 2026)*

Capital Structure (February 2026)

Common Shares	77,669,893
Warrants	15,230,596
Contingent Rights	8,000,000
Options	8,444,856
RSUs	2,150,582
Fully Diluted	111,495,927

Escrow Terms

- ~85% of shares are locked up and cannot be sold below the listing price for one year
- ~34% Escrowed common shares follow standard CSE escrow release schedule



Julia Becker

Vice President, Capital Markets

T: +1(604)785-0850

E: Julia@tempramed.com

Tamir Gedo

T: 972 54 427 1014

E: Gedo.tamir@outlook.com

Website: www.tempramed.com

Email: ir@tempramed.com